Needham & Company Downgrades Hyperion Therapeutics (HPTX) to Hold Amid Takeover Deal Mar 31, 2015 07:23AM
Needham & Company Maintains 'Buy' at Hyperion Therapeutics (HPTX) Sep 8, 2014 03:45PM
Hyperion Therapeutics (HPTX) Bullish Stance Reiterated at Needham & Company Amid Strong Q1 Ravicti Sales May 7, 2014 07:58AM
Hyperion Therapeutics (HPTX) Target, Estimate Raised at Needham & Company Feb 28, 2014 07:52AM
Hyperion Therapeutics (HPTX) PT Lifted to $35 at Needham & Company Aug 15, 2013 11:04AM


Mar 8, 2013 09:16AM Hyperion (HPTX) Prices 2.88M Common Follow-On Offering
Feb 26, 2013 09:06AM Needham & Company Maintains Buy on Hyperion Therapeutics (HPTX) Post Q4
Feb 4, 2013 03:12PM Needham & Company Raises PT on Hyperion Therapeutics (HPTX) to $25 after FDA Approval for Ravicti
Aug 20, 2012 10:57AM Notable Analyst Rating Changes 08/20: (ROST) (PB) (STO) Upgraded; (STEM) (STX) (PCYC) Downgraded
Aug 20, 2012 07:36AM Needham & Company Starts Hyperion Therapeutics (HPTX) at Buy; Commercial Opportunity for Navicti
Jul 26, 2012 11:11AM Hyperion Therapeutics (HPTX) IPO Trades Slightly Higher
Apr 13, 2012 06:46AM Hyperion Therapeutics (HPTX) Files $57.5M IPO